Equities

IFR US ECM Pricings

 |  Robert Sherwood

Celldex Therapeutics (US, biotech)  ─ $300m ABB. 10.3m shares (Primary) at $29.00 versus $29.00-$29.50 marketing and $31.26 last sale. LEER, TDC. Upsized from $250m. Wall cross. 

Topics
Americas North America Equity Capital ABBs and Block Trades Canada US Dollar United States Initial Public Offerings (IPO) Structured Equity Marketed Follow-Ons
Issuers
Celldex Therapeutics Inc (CLDX.O)